Skip to main content
. 2023 Jul 25;13(2):169–180. doi: 10.1159/000531744

Fig. 2.

Fig. 2.

Forest plot of NMA for OS of first-line systemic treatments for advanced HCC compared to atezolizumab plus bevacizumab. 30-month OS.